Articles from this edition:
Latest articles
GlaxoSmithKline’s Zejula (niraparib) approved for treatment of ovarian cancer
The European Commission has approved GlaxoSmithKline's (GSK) Zejula (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, as first-line monotherapy maintenance treatment for adult...
Ten top tips for pharma and healthcare to avoid data breaches
Every organisation is a software organisation but for healthcare providers and pharmaceutical organisations, the stakes are high when it comes to data breaches. In...
TherapeutAix expands R&D network to Alderley Analytical and Peak Proteins
Life sciences consultancy, TherapeutAix, has added contract research organisations (CROs), Alderley Analytical and Peak Proteins to its global R&D network. The partnership will form...
Popular articles
New Normal, New Thinking: Life Post COVID-19
New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
GlaxoSmithKline’s Zejula (niraparib) approved for treatment of ovarian cancer
The European Commission has approved GlaxoSmithKline's (GSK) Zejula (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, as first-line monotherapy maintenance treatment for adult...
Pfizer suffers huge data breach on unsecured cloud storage
Global pharmaceutical giant Pfizer Inc. has suffered a huge data breach, with patient information found exposed on unsecured cloud storage. The exposed data was...
Enter the Pf Awards 2021 today
The Pf Awards 2021 are open for entries!
New categories | New candidates | New opportunities to win
Would you like to win a national...
Ten top tips for pharma and healthcare to avoid data breaches
Every organisation is a software organisation but for healthcare providers and pharmaceutical organisations, the stakes are high when it comes to data breaches. In...